ABT vs ALT · P/E 25, rev $44.33B vs rev $20.0K
Abbott Laboratories (ABT) versus Altimmune Inc (ALT) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Altimmune Inc (ALT) is a biotechnology company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported ALT revenue for 2024-12-31 was $20.0K. Net income was -$95.1M. Revenue was down 95.3% from 2023-12-31 to 2024-12-31. ALT currently screens at market cap $527.0M.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. ALT currently screens at market cap $527.0M.
Not investment advice. Open the ABT and ALT stock pages for the full models.
Not investment advice.